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The role of palliative chemotherapy in metastatic non small cell 
lung cancer with brain metastases
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Background: The overall risk of developing brain metastases in 
non-small cell lung cancer (NSCLC) is 20%. Palliative chemotherapy 
improves the outcome of metastatic NSCLC but there is no evidence 
to support its use in the presence of brain metastases. A retrospective 
analysis of NSCLC patients with brain metastases was performed to 
determine the value of chemotherapy within this group of patients.
Methods: Patients with NSCLC who received palliative whole brain 
radiotherapy (WBRT) for brain metastasis between January 2002 and 
April 2005 were identiﬁed from the radiotherapy database. Case notes 
and electronic records were analysed retrospectively. The primary 
endpoint was overall survival (OS) calculated from the date of con-
ﬁrmation of brain metastases and estimated using the Kaplan-Meier 
method. A multivariate analysis was performed using Cox regression to 
examine the effect of prognostic variables.
Results: A total of 162 patients were identiﬁed. 87 patients (53.7%) 
had brain metastases at presentation. In addition to WBRT, 4 patients 
(2.5%) underwent surgical resection of brain metastases. 1 patient had 
stereotactic radiosurgery. 59 patients (36.4%) received chemotherapy 
following WBRT. The median number of cycles of chemotherapy 
administered following WBRT was 3 (range 1-6). Median OS was 3.84 
months (95% CI 3.22 to 4.83 months) and 1 year survival 9.3%. Pa-
tients who were performance status (PS) 0-1 had a median OS of 6.47 
months versus 2.63 months for those who were PS 2-3 (HR=2.08; 95% 
CI 1.48 to 2.92; p<0.0001). Patients receiving chemotherapy following 
WBRT had a median OS of 6.47 months versus 2.60 months for those 
who did not receive chemotherapy (HR=0.45; 95% CI 0.32 to 0.63; 
p<0.0001). In multivariate analysis, chemotherapy following WBRT 
remained a signiﬁcant favourable prognostic factor after controlling for 
performance status, age, histological subtype, number and sites of brain 
metastases, synchronicity of brain metastases, dose of radiotherapy and 
presence of other distant metastases.
Conclusion: Palliative chemotherapy following WBRT in patients with 
metastatic NSCLC with brain metastases improves survival and should 
be considered in good performance status patients.
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A phase II study of vinorelbine monotherapy in the treatment of 
advanced non-small cell lung cancer in elderly Chinese population
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tal, Hong Kong, China
Introduction: Non-small cell lung cancer (NSCLC) has accounted 
for more than 3,000 new cases each year in Hong Kong with 5-year 
survival less than 15%. Chemotherapy is currently the “gold standard” 
treatment for advanced disease in those relatively young ( <70 years 
old) with good performance status. However the beneﬁt of chemo-
therapy in the elderly has been limited by the concerns about toxicities, 
which may have ethnic differences. 
Method: A phase II single-centered open-labelled study, using vinorel-
bine (30mg/m2 ivi on day 1 and 8, every 3 weeks, for 6 cycles) in 
chemonaive elderly Chinese patients (>70 years old) with cytologically 
or histologically conﬁrmed stage IIIB/IV NSCLC. 
Results: There were 18 patients recruited (age 74 ± 3 years, 10 males, 
33% never smokers) with good performance status (all in WHO 0 
or 1). The majority of cases were adenocarcinomas (56%) and more 
than two-thirds in stage IIIB. Dose reduction was required because of 
myelosuppression in 9.9%. The median number of cycles administered 
was 4, with 6 patients managed to complete 6 cycles of chemotherapy. 
The objective tumour response rate was 11.1% with 33.3% stable 
disease. The median survival was 10 months. Signiﬁcant grade 3/4 
toxicities occurred in neutropenia (68%), anaemia (1%), and phlebitis 
(4%). There was no treatment-related death.
Conclusion: Vinorelbine as a single agent is active in the treatment 
of advanced NSCLC in the elderly Chinese with acceptable toxicity 
proﬁle. Future study comparing with combination chemotherapy is 
warranted.
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A feasibility study of adjuvant carboplatin (C) plus gemcitabine 
(G) in completely resected stage IB-III non-small-cell lung cancer 
(NSCLC)
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Background: In recent randomized phase III trials in early-stage 
NSCLC, cisplatin-based adjuvant chemotherapy resulted in a 4.1-15% 
5-year survival beneﬁt versus observation. However, only 56-74% of 
patients completed planned treatment, suggestive of poor compliance. 
C plus G (CG), one of the standard regimens for advanced NSCLC, is 
considered more tolerable than other platinum-based regimens because 
it is associated with less nausea/vomiting, sensory neuropathy, and 
alopecia. The objective of this study was to assess the feasibility and 
safety of adjuvant CG in patients with completely resected NSCLC. 
Methods: Eligibility criteria included histologically conﬁrmed 
NSCLC, age 20-74 years, complete surgical resection, post-operative 
pathological stage IB-III, 4-8 weeks post-surgery, ECOG performance 
status (PS) 0-1, adequate organ function, and informed consent. Pa-
tients were treated with adjuvant CG (C, AUC=5 on day 1; G, 1,000 
mg/m2 on days 1 and 8) every 3 weeks for 4 cycles. The primary 
endpoint was treatment compliance, and the planned sample size was 
35 patients (Simon’s minimax design). 
Results: From October 2004 to July 2006, 35 patients (17 males, 18 
females; median age, 64 years) were enrolled. All patients had PS=0. 
Histologic types included adenocarcinoma (n=27), squamous cell 
carcinoma (n=3), large cell neuroendocrine carcinoma (n=3), large cell 
carcinoma (n=1), and adenosquamous carcinoma (n=1). Pathological 
stages included stage IB (n=7), stage IIA (n=7), stage IIB (n=4), stage 
IIIA (n=13), and stage IIIB (n=4). Resection consisted of lobectomy 
(n=33) and pneumonectomy (n=2). All patients received ≥2 cycles 
of chemotherapy, with 29 patients (83%) completing 3 or 4 cycles. 
Primary G3/4 toxicities were leukopenia (51%), neutropenia (83%), 
thrombocytopenia (71%), and anemia (38%). Nonhematologic toxici-
